evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 40%GRADE not reported 0 · 0%Very low 2 · 40%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Infliximab vs placebo

Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

It is very uncertain whether infliximab changes loss of clinical response (at 32 weeks, less than 70 points in CDAI… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab vs adalimumab

Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).

1 finding from 1 review

Infliximab vs biosimilar

Loss of clinical response (at 52 weeks, HBI change from baseline of less than 4 points and a total score of less than 7 points) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Infliximab may leads to higher loss of clinical response (at 52 weeks, HBI change from baseline of… compared with biosimilar (low certainty).

1 finding from 1 review